{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T05:16:08Z","timestamp":1788153368344,"version":"build-2803163510"},"reference-count":113,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T00:00:00Z","timestamp":1781913600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T00:00:00Z","timestamp":1788134400000},"content-version":"vor","delay-in-days":72,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"DOI":"10.1186\/s13063-026-09855-5","type":"journal-article","created":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T00:47:28Z","timestamp":1781916448000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["CHIP-AML22: a complex clinical trial in de novo pediatric AML patients, including a gemtuzumab ozogamicin randomization and targeted therapy with quizartinib in eligible subgroups, within the NOPHO-DB-SHIP consortium"],"prefix":"10.1186","volume":"27","author":[{"given":"Gertjan J.L.","family":"Kaspers","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merlijn","family":"van Hamel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonas","family":"Abrahamsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nira","family":"Arad-Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renske","family":"Benedictus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nastassja","family":"Scheidegger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Castillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Ka Leung Cheuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vitor","family":"Costa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yvonne","family":"Duong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose Maria","family":"Fernandez Navarro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Fogelstrand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bianca F.","family":"Goemans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sae","family":"Ishimaru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olafur Gisli","family":"Jonsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristian L.","family":"Juul-Dam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maarja","family":"Karu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joost B.","family":"Koedijk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhanna","family":"Kovalova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"De Moerloose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica Cheng","family":"Munthe-Kaas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sauli","family":"Palmu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramune","family":"Pasauliene","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Tierens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harm","family":"van Tinteren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominik","family":"Turkiewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daria G.","family":"Valerio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noa","family":"Wijnen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. Michel","family":"Zwaan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cornelis Jan","family":"Pronk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,20]]},"reference":[{"issue":"1","key":"9855_CR1","doi-asserted-by":"publisher","first-page":"127","DOI":"10.3390\/jcm4010127","volume":"4","author":"JD de Rooij","year":"2015","unstructured":"de Rooij JD, Zwaan CM, van den Heuvel-Eibrink M. Pediatric AML: from biology to clinical management. J Clin Med. 2015;4(1):127\u201349.","journal-title":"J Clin Med"},{"key":"9855_CR2","doi-asserted-by":"publisher","unstructured":"Reinhardt D, Antoniou E, Waack K. Pediatric Acute Myeloid Leukemia-Past, Present, and Future. J Clin Med. 2022;11(3):504. https:\/\/doi.org\/10.3390\/jcm11030504. PMID: 35159956; PMCID: PMC8837075.","DOI":"10.3390\/jcm11030504"},{"key":"9855_CR3","unstructured":"National Cancer Institute. Childhood acute myeloid leukemia treatment (PDQ\u00ae)\u2013Health professional version [Internet]. 2024 Last updated 09\u201316\u20132024 Accessed 11\u201311\u20132024]; Available from: https:\/\/www.cancer.gov\/types\/leukemia\/hp\/child-aml-treatment-pdq#_1031_toc."},{"issue":"9","key":"9855_CR4","first-page":"2275","volume":"108","author":"G Egan","year":"2023","unstructured":"Egan G, Tasian SK. Relapsed pediatric acute myeloid leukaemia: state-of-the-art in 2023. Haematologica. 2023;108(9):2275\u201388.","journal-title":"Haematologica"},{"issue":"18","key":"9855_CR5","doi-asserted-by":"publisher","first-page":"2174","DOI":"10.1200\/JCO.23.01841","volume":"42","author":"A Tierens","year":"2024","unstructured":"Tierens A, et al. Mitoxantrone versus liposomal daunorubicin in induction of pediatric AML with risk stratification based on flow cytometry measurement of residual disease. J Clin Oncol. 2024;42(18):2174\u201385.","journal-title":"J Clin Oncol"},{"issue":"12","key":"9855_CR6","doi-asserted-by":"publisher","first-page":"3907","DOI":"10.1182\/blood.V96.12.3907","volume":"96","author":"M Mizuki","year":"2000","unstructured":"Mizuki M, et al. Flt3 mutations from patients with acute myeloid leukemia induce transformation of 32D cells mediated by the Ras and STAT5 pathways. Blood. 2000;96(12):3907\u201314.","journal-title":"Blood"},{"issue":"7","key":"9855_CR7","doi-asserted-by":"publisher","first-page":"2387","DOI":"10.1182\/blood-2002-12-3627","volume":"102","author":"CM Zwaan","year":"2003","unstructured":"Zwaan CM, et al. FLT3 internal tandem duplication in 234 children with acute myeloid leukemia: prognostic significance and relation to cellular drug resistance. Blood. 2003;102(7):2387\u201394.","journal-title":"Blood"},{"issue":"1","key":"9855_CR8","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1182\/blood.V97.1.89","volume":"97","author":"S Meshinchi","year":"2001","unstructured":"Meshinchi S, et al. Prevalence and prognostic significance of Flt3 internal tandem duplication in pediatric acute myeloid leukemia. Blood. 2001;97(1):89\u201394.","journal-title":"Blood"},{"issue":"12","key":"9855_CR9","doi-asserted-by":"publisher","first-page":"3654","DOI":"10.1182\/blood-2006-03-009233","volume":"108","author":"S Meshinchi","year":"2006","unstructured":"Meshinchi S, et al. Clinical implications of FLT3 mutations in pediatric AML. Blood. 2006;108(12):3654\u201361.","journal-title":"Blood"},{"issue":"2","key":"9855_CR10","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1038\/leu.2008.313","volume":"23","author":"IH Hollink","year":"2009","unstructured":"Hollink IH, et al. Favorable prognostic impact of NPM1 gene mutations in childhood acute myeloid leukemia, with emphasis on cytogenetically normal AML. Leukemia. 2009;23(2):262\u201370.","journal-title":"Leukemia"},{"issue":"1","key":"9855_CR11","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1038\/nm.4439","volume":"24","author":"H Bolouri","year":"2018","unstructured":"Bolouri H, et al. The molecular landscape of pediatric acute myeloid leukemia reveals recurrent structural alterations and age-specific mutational interactions. Nat Med. 2018;24(1):103\u201312.","journal-title":"Nat Med"},{"issue":"2","key":"9855_CR12","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1038\/s41375-018-0357-9","volume":"33","author":"N Daver","year":"2019","unstructured":"Daver N, et al. Targeting FLT3 mutations in AML: review of current knowledge and evidence. Leukemia. 2019;33(2):299\u2013312.","journal-title":"Leukemia"},{"issue":"7","key":"9855_CR13","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1016\/S1470-2045(19)30150-0","volume":"20","author":"JE Cortes","year":"2019","unstructured":"Cortes JE, et al. Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2019;20(7):984\u201397.","journal-title":"Lancet Oncol"},{"issue":"10388","key":"9855_CR14","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1016\/S0140-6736(23)00464-6","volume":"401","author":"HP Erba","year":"2023","unstructured":"Erba HP, et al. Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023;401(10388):1571\u201383.","journal-title":"Lancet"},{"key":"9855_CR15","unstructured":"FDA. FDA approves quizartinib for newly diagnosed acute myeloid leukemia. 2023 Last updated: 07\u201320\u20132023 Accessed: 21\u201310\u20132024]; Available from: https:\/\/www.fda.gov\/drugs\/drug-approvals-and-databases\/fda-approves-quizartinib-newly-diagnosed-acute-myeloid-leukemia."},{"key":"9855_CR16","unstructured":"EMA. Vanflyta: EPAR. Accessed: 05\u201312\u20132024]; Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/vanflyta."},{"issue":"16","key":"9855_CR17","doi-asserted-by":"publisher","first-page":"4014","DOI":"10.1158\/1078-0432.CCR-15-1998","volume":"22","author":"TM Cooper","year":"2016","unstructured":"Cooper TM, et al. A phase I study of quizartinib combined with chemotherapy in relapsed childhood leukemia: a Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Study. Clin Cancer Res. 2016;22(16):4014\u201322.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"9855_CR18","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1158\/2643-3230.BCD-20-0143","volume":"2","author":"AS Alotaibi","year":"2021","unstructured":"Alotaibi AS, et al. Patterns of resistance differ in patients with acute myeloid leukemia treated with type I versus type II FLT3 inhibitors. Blood Cancer Discov. 2021;2(2):125\u201334.","journal-title":"Blood Cancer Discov"},{"key":"9855_CR19","doi-asserted-by":"crossref","unstructured":"Daver N, et al. Secondary mutations as mediators of resistance to targeted therapy in leukemia. Blood. 2015;125(21):3236\u201345.","DOI":"10.1182\/blood-2014-10-605808"},{"issue":"2","key":"9855_CR20","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1182\/blood.V96.2.483.014k40_483_490","volume":"96","author":"SP Paul","year":"2000","unstructured":"Paul SP, et al. Myeloid specific human CD33 is an inhibitory receptor with differential ITIM function in recruiting the phosphatases SHP-1 and SHP-2. Blood. 2000;96(2):483\u201390.","journal-title":"Blood"},{"issue":"6","key":"9855_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2014.39","volume":"4","author":"A Ehninger","year":"2014","unstructured":"Ehninger A, et al. Distribution and levels of cell surface expression of CD33 and CD123 in acute myeloid leukemia. Blood Cancer J. 2014;4(6):e218.","journal-title":"Blood Cancer J"},{"issue":"4","key":"9855_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.beha.2020.101224","volume":"33","author":"MC Clark","year":"2020","unstructured":"Clark MC, Stein A. CD33 directed bispecific antibodies in acute myeloid leukemia. Best Pract Res Clin Haematol. 2020;33(4):101224.","journal-title":"Best Pract Res Clin Haematol"},{"key":"9855_CR23","doi-asserted-by":"publisher","unstructured":"Gottardi M, Simonetti G, Sperotto A, Nappi D, Ghelli Luserna di Ror\u00e0 A, Padella A, Norata M, Giannini MB, Musuraca G, Lanza F, Cerchione C, Martinelli G. Therapeutic Targeting of Acute Myeloid Leukemia by Gemtuzumab Ozogamicin. Cancers (Basel). 2021;13(18):4566.\u00a0https:\/\/doi.org\/10.3390\/cancers13184566. PMID: 34572794; PMCID: PMC8469571.","DOI":"10.3390\/cancers13184566"},{"issue":"1","key":"9855_CR24","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1021\/bc010021y","volume":"13","author":"PR Hamann","year":"2002","unstructured":"Hamann PR, et al. Gemtuzumab ozogamicin, a potent and selective anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia. Bioconjug Chem. 2002;13(1):47\u201358.","journal-title":"Bioconjug Chem"},{"issue":"22","key":"9855_CR25","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1182\/blood.V114.22.790.790","volume":"114","author":"S Petersdorf","year":"2009","unstructured":"Petersdorf S, et al. Preliminary Results of Southwest Oncology Group Study S0106: An international intergroup phase 3 randomized trial comparing the addition of gemtuzumab ozogamicin to standard induction therapy versus standard induction therapy followed by a second randomization to post-consolidation gemtuzumab ozogamicin versus no additional therapy for previously untreated acute myeloid leukemia. Blood. 2009;114(22):790.","journal-title":"Blood"},{"issue":"5","key":"9855_CR26","doi-asserted-by":"publisher","first-page":"e171","DOI":"10.1634\/theoncologist.2019-0025","volume":"24","author":"S Ali","year":"2019","unstructured":"Ali S, et al. The EMA review of mylotarg (gemtuzumab ozogamicin) for the treatment of acute myeloid leukemia. Oncologist. 2019;24(5):e171\u20139.","journal-title":"Oncologist"},{"issue":"30","key":"9855_CR27","doi-asserted-by":"publisher","first-page":"3199","DOI":"10.2217\/fon-2018-0325","volume":"14","author":"M Gbadamosi","year":"2018","unstructured":"Gbadamosi M, Meshinchi S, Lamba JK. Gemtuzumab ozogamicin for treatment of newly diagnosed CD33-positive acute myeloid leukemia. Future Oncol. 2018;14(30):3199\u2013213.","journal-title":"Future Oncol"},{"issue":"1","key":"9855_CR28","doi-asserted-by":"publisher","first-page":"113","DOI":"10.3324\/haematol.2018.188888","volume":"104","author":"J Lambert","year":"2019","unstructured":"Lambert J, et al. Gemtuzumab ozogamicin for de novo acute myeloid leukemia: final efficacy and safety updates from the open-label, phase III ALFA-0701 trial. Haematologica. 2019;104(1):113\u20139.","journal-title":"Haematologica"},{"key":"9855_CR29","doi-asserted-by":"publisher","first-page":"297","DOI":"10.2147\/OTT.S263829","volume":"16","author":"NE Wijnen","year":"2023","unstructured":"Wijnen NE, et al. Treating CD33-positive de novo acute myeloid leukemia in pediatric patients: focus on the clinical value of gemtuzumab ozogamicin. Onco Targets Ther. 2023;16:297\u2013308.","journal-title":"Onco Targets Ther"},{"issue":"27","key":"9855_CR30","doi-asserted-by":"publisher","first-page":"3021","DOI":"10.1200\/JCO.2014.55.3628","volume":"32","author":"AS Gamis","year":"2014","unstructured":"Gamis AS, et al. Gemtuzumab ozogamicin in children and adolescents with de novo acute myeloid leukemia improves event-free survival by reducing relapse risk: results from the randomized phase III Children\u2019s Oncology Group trial AAML0531. J Clin Oncol. 2014;32(27):3021\u201332.","journal-title":"J Clin Oncol"},{"issue":"3","key":"9855_CR31","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1002\/cncr.26190","volume":"118","author":"TM Cooper","year":"2012","unstructured":"Cooper TM, et al. AAML03P1, a pilot study of the safety of gemtuzumab ozogamicin in combination with chemotherapy for newly diagnosed childhood acute myeloid leukemia: a report from the Children\u2019s Oncology Group. Cancer. 2012;118(3):761\u20139.","journal-title":"Cancer"},{"issue":"22","key":"9855_CR32","doi-asserted-by":"publisher","first-page":"4036","DOI":"10.1002\/cncr.28334","volume":"119","author":"C O'Hear","year":"2013","unstructured":"O\u2019Hear C, et al. Gemtuzumab ozogamicin can reduce minimal residual disease in patients with childhood acute myeloid leukemia. Cancer. 2013;119(22):4036\u201343.","journal-title":"Cancer"},{"issue":"7","key":"9855_CR33","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1182\/blood-2017-01-762336","volume":"130","author":"EM Guest","year":"2017","unstructured":"Guest EM, et al. Gemtuzumab ozogamicin in infants with AML: results from the Children\u2019s Oncology Group trials AAML03P1 and AAML0531. Blood. 2017;130(7):943\u20135.","journal-title":"Blood"},{"issue":"1","key":"9855_CR34","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1038\/leu.2012.229","volume":"27","author":"AK Burnett","year":"2013","unstructured":"Burnett AK, et al. The addition of gemtuzumab ozogamicin to low-dose Ara-C improves remission rate but does not significantly prolong survival in older patients with acute myeloid leukaemia: results from the LRF AML14 and NCRI AML16 pick-a-winner comparison. Leukemia. 2013;27(1):75\u201381.","journal-title":"Leukemia"},{"issue":"9","key":"9855_CR35","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1016\/S1470-2045(14)70281-5","volume":"15","author":"RK Hills","year":"2014","unstructured":"Hills RK, et al. Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials. Lancet Oncol. 2014;15(9):986\u201396.","journal-title":"Lancet Oncol"},{"issue":"4","key":"9855_CR36","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1200\/JCO.2010.31.4310","volume":"29","author":"AK Burnett","year":"2011","unstructured":"Burnett AK, et al. Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial. J Clin Oncol. 2011;29(4):369\u201377.","journal-title":"J Clin Oncol"},{"issue":"28","key":"9855_CR37","doi-asserted-by":"publisher","first-page":"3149","DOI":"10.1200\/JCO.20.03048","volume":"39","author":"JA Pollard","year":"2021","unstructured":"Pollard JA, et al. Gemtuzumab ozogamicin improves event-free survival and reduces relapse in pediatric KMT2A-rearranged AML: results from the phase III children\u2019s oncology group trial AAML0531. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2021;39(28):3149\u201360.","journal-title":"Journal of clinical oncology: official journal of the American Society of Clinical Oncology"},{"issue":"8","key":"9855_CR38","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.1158\/1078-0432.CCR-15-1349","volume":"22","author":"K Tarlock","year":"2016","unstructured":"Tarlock K, et al. Gemtuzumab ozogamicin reduces relapse risk in FLT3\/ITD acute myeloid leukemia: a report from the Children\u2019s Oncology Group. Clin Cancer Res. 2016;22(8):1951\u20137.","journal-title":"Clin Cancer Res"},{"issue":"7","key":"9855_CR39","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1200\/JCO.2015.62.6846","volume":"34","author":"JA Pollard","year":"2016","unstructured":"Pollard JA, et al. CD33 expression and its association with gemtuzumab ozogamicin response: results from the randomized phase III Children\u2019s Oncology Group Trial AAML0531. J Clin Oncol. 2016;34(7):747\u201355.","journal-title":"J Clin Oncol"},{"issue":"16","key":"9855_CR40","doi-asserted-by":"publisher","first-page":"3705","DOI":"10.1182\/blood-2011-12-398370","volume":"119","author":"JA Pollard","year":"2012","unstructured":"Pollard JA, et al. Correlation of CD33 expression level with disease characteristics and response to gemtuzumab ozogamicin containing chemotherapy in childhood AML. Blood. 2012;119(16):3705\u201311.","journal-title":"Blood"},{"issue":"17","key":"9855_CR41","doi-asserted-by":"publisher","first-page":"2157","DOI":"10.1182\/blood-2016-01-689976","volume":"127","author":"G Olombel","year":"2016","unstructured":"Olombel G, et al. The level of blast CD33 expression positively impacts the effect of gemtuzumab ozogamicin in patients with acute myeloid leukemia. Blood. 2016;127(17):2157\u201360.","journal-title":"Blood"},{"issue":"5","key":"9855_CR42","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1038\/leu.2016.309","volume":"31","author":"N Khan","year":"2017","unstructured":"Khan N, et al. Expression of CD33 is a predictive factor for effect of gemtuzumab ozogamicin at different doses in adult acute myeloid leukaemia. Leukemia. 2017;31(5):1059\u201368.","journal-title":"Leukemia"},{"issue":"2","key":"9855_CR43","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1038\/leu.2008.185","volume":"23","author":"JK Lamba","year":"2009","unstructured":"Lamba JK, et al. Coding polymorphisms in CD33 and response to gemtuzumab ozogamicin in pediatric patients with AML: a pilot study. Leukemia. 2009;23(2):402\u20134.","journal-title":"Leukemia"},{"issue":"23","key":"9855_CR44","doi-asserted-by":"publisher","first-page":"2674","DOI":"10.1200\/JCO.2016.71.2513","volume":"35","author":"JK Lamba","year":"2017","unstructured":"Lamba JK, et al. CD33 splicing polymorphism determines gemtuzumab ozogamicin response in de novo acute myeloid leukemia: report from randomized phase III Children\u2019s Oncology Group Trial AAML0531. J Clin Oncol. 2017;35(23):2674\u201382.","journal-title":"J Clin Oncol"},{"key":"9855_CR45","doi-asserted-by":"publisher","unstructured":"Chauhan L, Shin M, Wang YC, Loken M, Pollard J, Aplenc R, Hirsch BA, Raimondi S, Ries RE, Bernstein ID, Gamis AS, Alonzo TA, Meshinchi S, Lamba JK. CD33_PGx6_Score Predicts Gemtuzumab Ozogamicin Response in Childhood Acute Myeloid Leukemia: A Report From the Children's Oncology Group. JCO Precis Oncol. 2019;3:PO.18.00387.\u00a0https:\/\/doi.org\/10.1200\/PO.18.00387. PMID: 32914031; PMCID: PMC7446480.","DOI":"10.1200\/PO.18.00387"},{"issue":"6","key":"9855_CR46","doi-asserted-by":"publisher","first-page":"1620","DOI":"10.1158\/1078-0432.CCR-12-3115","volume":"19","author":"L Mortland","year":"2013","unstructured":"Mortland L, et al. Clinical significance of CD33 nonsynonymous single-nucleotide polymorphisms in pediatric patients with acute myeloid leukemia treated with gemtuzumab-ozogamicin-containing chemotherapy. Clin Cancer Res. 2013;19(6):1620\u20137.","journal-title":"Clin Cancer Res"},{"issue":"5","key":"9855_CR47","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1182\/blood-2012-03-416701","volume":"120","author":"H Hasle","year":"2012","unstructured":"Hasle H, et al. Gemtuzumab ozogamicin as postconsolidation therapy does not prevent relapse in children with AML: results from NOPHO-AML 2004. Blood. 2012;120(5):978\u201384.","journal-title":"Blood"},{"issue":"2","key":"9855_CR48","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1586\/14737140.2016.1129903","volume":"16","author":"J Parigger","year":"2016","unstructured":"Parigger J, et al. Dose-related efficacy and toxicity of gemtuzumab ozogamicin in pediatric acute myeloid leukemia. Expert Rev Anticancer Ther. 2016;16(2):137\u201346.","journal-title":"Expert Rev Anticancer Ther"},{"issue":"1","key":"9855_CR49","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1186\/s13045-020-00975-2","volume":"13","author":"JE Cortes","year":"2020","unstructured":"Cortes JE, et al. Prevention, recognition, and management of adverse events associated with gemtuzumab ozogamicin use in acute myeloid leukemia. J Hematol Oncol. 2020;13(1):137.","journal-title":"J Hematol Oncol"},{"issue":"12","key":"9855_CR50","doi-asserted-by":"publisher","first-page":"1890","DOI":"10.1001\/jamaoncol.2020.4600","volume":"6","author":"NJ Short","year":"2020","unstructured":"Short NJ, et al. Association of measurable residual disease with survival outcomes in patients with acute myeloid leukemia: a systematic review and meta-analysis. JAMA Oncol. 2020;6(12):1890\u20139.","journal-title":"JAMA Oncol"},{"issue":"27","key":"9855_CR51","doi-asserted-by":"publisher","first-page":"2949","DOI":"10.1200\/JCO.2015.62.8289","volume":"33","author":"CM Zwaan","year":"2015","unstructured":"Zwaan CM, et al. Collaborative efforts driving progress in pediatric acute myeloid leukemia. J Clin Oncol. 2015;33(27):2949\u201362.","journal-title":"J Clin Oncol"},{"issue":"12","key":"9855_CR52","doi-asserted-by":"publisher","first-page":"2489","DOI":"10.1182\/blood-2009-04-215152","volume":"114","author":"BV Balgobind","year":"2009","unstructured":"Balgobind BV, et al. Novel prognostic subgroups in childhood 11q23\/MLL-rearranged acute myeloid leukemia: results of an international retrospective study. Blood. 2009;114(12):2489\u201396.","journal-title":"Blood"},{"issue":"5","key":"9855_CR53","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1038\/s41375-023-01877-1","volume":"37","author":"C Meyer","year":"2023","unstructured":"Meyer C, et al. The KMT2A recombinome of acute leukemias in 2023. Leukemia. 2023;37(5):988\u20131005.","journal-title":"Leukemia"},{"issue":"16","key":"9855_CR54","doi-asserted-by":"publisher","first-page":"2963","DOI":"10.1200\/JCO.22.02120","volume":"41","author":"RE van Weelderen","year":"2023","unstructured":"van Weelderen RE, et al. Measurable residual disease and fusion partner independently predict survival and relapse risk in childhood KMT2A-rearranged acute myeloid leukemia: a study by the International Berlin-Frankfurt-M\u00fcnster Study Group. J Clin Oncol. 2023;41(16):2963\u201374.","journal-title":"J Clin Oncol"},{"issue":"26","key":"9855_CR55","doi-asserted-by":"publisher","first-page":"7102","DOI":"10.1182\/blood-2010-12-328302","volume":"117","author":"EA Coenen","year":"2011","unstructured":"Coenen EA, et al. Prognostic significance of additional cytogenetic aberrations in 733 de novo pediatric 11q23\/MLL-rearranged AML patients: results of an international study. Blood. 2011;117(26):7102\u201311.","journal-title":"Blood"},{"issue":"16","key":"9855_CR56","doi-asserted-by":"publisher","first-page":"2682","DOI":"10.1200\/JCO.2009.25.6321","volume":"28","author":"C von Neuhoff","year":"2010","unstructured":"von Neuhoff C, et al. Prognostic impact of specific chromosomal aberrations in a large group of pediatric patients with acute myeloid leukemia treated uniformly according to trial AML-BFM 98. J Clin Oncol. 2010;28(16):2682\u20139.","journal-title":"J Clin Oncol"},{"key":"9855_CR57","doi-asserted-by":"crossref","unstructured":"Gruber, T.A., et al., An Inv(16)(p13.3q24.3)-encoded CBFA2T3-GLIS2 fusion protein defines an aggressive subtype of pediatric acute megakaryoblastic leukemia. Cancer Cell. 2012;22(5): 683\u201397.","DOI":"10.1016\/j.ccr.2012.10.007"},{"issue":"17","key":"9855_CR58","doi-asserted-by":"publisher","first-page":"3469","DOI":"10.1182\/blood-2012-11-469825","volume":"121","author":"R Masetti","year":"2013","unstructured":"Masetti R, et al. CBFA2T3-GLIS2 fusion transcript is a novel common feature in pediatric, cytogenetically normal AML, not restricted to FAB M7 subtype. Blood. 2013;121(17):3469\u201372.","journal-title":"Blood"},{"issue":"3","key":"9855_CR59","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1158\/1078-0432.CCR-19-1800","volume":"26","author":"JL Smith","year":"2020","unstructured":"Smith JL, et al. Comprehensive transcriptome profiling of cryptic CBFA2T3-GLIS2 fusion-positive AML defines novel therapeutic options: a COG and TARGET Pediatric AML Study. Clin Cancer Res. 2020;26(3):726\u201337.","journal-title":"Clin Cancer Res"},{"issue":"10","key":"9855_CR60","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.1038\/leu.2016.119","volume":"30","author":"L Eidenschink Brodersen","year":"2016","unstructured":"Eidenschink Brodersen L, et al. A recurrent immunophenotype at diagnosis independently identifies high-risk pediatric acute myeloid leukemia: a report from Children\u2019s Oncology Group. Leukemia. 2016;30(10):2077\u201380.","journal-title":"Leukemia"},{"issue":"2","key":"9855_CR61","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1002\/cyto.b.21943","volume":"100","author":"D Panda","year":"2021","unstructured":"Panda D, et al. Utility of CD36 as a novel addition to the immunophenotypic signature of RAM-phenotype acute myeloid leukemia and study of its clinicopathological characteristics. Cytometry B Clin Cytom. 2021;100(2):206\u201317.","journal-title":"Cytometry B Clin Cytom"},{"issue":"1","key":"9855_CR62","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1002\/cyto.b.21829","volume":"98","author":"LM Pardo","year":"2020","unstructured":"Pardo LM, et al. Deciphering the significance of CD56 expression in pediatric acute myeloid leukemia: a report from the Children\u2019s Oncology Group. Cytometry B Clin Cytom. 2020;98(1):52\u20136.","journal-title":"Cytometry B Clin Cytom"},{"key":"9855_CR63","doi-asserted-by":"publisher","first-page":"3393","DOI":"10.1182\/blood-2022-167680","volume":"140","author":"A Lamble","year":"2022","unstructured":"Lamble A, et al. Expanding the high-risk definition for children with newly diagnosed acute myeloid leukemia. Blood. 2022;140:3393\u20134.","journal-title":"Blood"},{"key":"9855_CR64","doi-asserted-by":"publisher","unstructured":"Tomizawa D, Tsujimoto SI. Risk-Stratified Therapy for Pediatric Acute Myeloid Leukemia. Cancers (Basel). 2023;15(16):4171.\u00a0https:\/\/doi.org\/10.3390\/cancers15164171. PMID: 37627199; PMCID: PMC10452723.","DOI":"10.3390\/cancers15164171"},{"issue":"3","key":"9855_CR65","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1080\/14737140.2018.1428091","volume":"18","author":"K Klein","year":"2018","unstructured":"Klein K, de Haas V, Kaspers GJL. Clinical challenges in de novo pediatric acute myeloid leukemia. Expert Rev Anticancer Ther. 2018;18(3):277\u201393.","journal-title":"Expert Rev Anticancer Ther"},{"issue":"3","key":"9855_CR66","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1007\/s11899-011-0094-x","volume":"6","author":"JM Fulbright","year":"2011","unstructured":"Fulbright JM, et al. Late effects of childhood leukemia therapy. Curr Hematol Malig Rep. 2011;6(3):195\u2013205.","journal-title":"Curr Hematol Malig Rep"},{"issue":"8","key":"9855_CR67","first-page":"2258","volume":"35","author":"NS Bhatt","year":"2021","unstructured":"Bhatt NS, et al. Late outcomes in survivors of childhood acute myeloid leukemia: a report from the St. Jude Lifetime Cohort Study Leukemia. 2021;35(8):2258\u201373.","journal-title":"Jude Lifetime Cohort Study Leukemia"},{"issue":"2","key":"9855_CR68","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1111\/bjh.14419","volume":"176","author":"H Hasle","year":"2017","unstructured":"Hasle H, Kaspers GJ. Strategies for reducing the treatment-related physical burden of childhood acute myeloid leukaemia - a review. Br J Haematol. 2017;176(2):168\u201378.","journal-title":"Br J Haematol"},{"issue":"1","key":"9855_CR69","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1200\/JCO.18.00313","volume":"37","author":"KD Getz","year":"2019","unstructured":"Getz KD, et al. Occurrence of treatment-related cardiotoxicity and its impact on outcomes among children treated in the AAML0531 clinical trial: a report from the Children\u2019s Oncology Group. J Clin Oncol. 2019;37(1):12\u201321.","journal-title":"J Clin Oncol"},{"issue":"9","key":"9855_CR70","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.1002\/cncr.23405","volume":"112","author":"DA Mulrooney","year":"2008","unstructured":"Mulrooney DA, et al. Twenty years of follow-up among survivors of childhood and young adult acute myeloid leukemia: a report from the Childhood Cancer Survivor Study. Cancer. 2008;112(9):2071\u20139.","journal-title":"Cancer"},{"issue":"4","key":"9855_CR71","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1002\/pbc.24881","volume":"61","author":"KA Schultz","year":"2014","unstructured":"Schultz KA, et al. Health conditions and quality of life in survivors of childhood acute myeloid leukemia comparing post remission chemotherapy to BMT: a report from the children\u2019s oncology group. Pediatr Blood Cancer. 2014;61(4):729\u201336.","journal-title":"Pediatr Blood Cancer"},{"issue":"9","key":"9855_CR72","doi-asserted-by":"publisher","first-page":"4454","DOI":"10.1002\/cam4.2337","volume":"8","author":"R Nagarajan","year":"2019","unstructured":"Nagarajan R, et al. Quality of life in pediatric acute myeloid leukemia: report from the Children\u2019s Oncology Group. Cancer Med. 2019;8(9):4454\u201364.","journal-title":"Cancer Med"},{"key":"9855_CR73","doi-asserted-by":"crossref","unstructured":"Stevens, R.F., et al., Marked improvements in outcome with chemotherapy alone in paediatric acute myeloid leukemia: results of the United Kingdom Medical Research Council\u2019s 10th AML trial. MRC Childhood Leukaemia Working Party. Br J Haematol. 1998; 101(1): 130\u201340.","DOI":"10.1046\/j.1365-2141.1998.00677.x"},{"issue":"12","key":"9855_CR74","doi-asserted-by":"publisher","first-page":"2090","DOI":"10.1038\/sj.leu.2403962","volume":"19","author":"SO Lie","year":"2005","unstructured":"Lie SO, et al. Long-term results in children with AML: NOPHO-AML Study Group\u2013report of three consecutive trials. Leukemia. 2005;19(12):2090\u2013100.","journal-title":"Leukemia"},{"issue":"2","key":"9855_CR75","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1002\/pbc.20944","volume":"49","author":"D Tomizawa","year":"2007","unstructured":"Tomizawa D, et al. Repetitive cycles of high-dose cytarabine are effective for childhood acute myeloid leukemia: long-term outcome of the children with AML treated on two consecutive trials of Tokyo Children\u2019s Cancer Study Group. Pediatr Blood Cancer. 2007;49(2):127\u201332.","journal-title":"Pediatr Blood Cancer"},{"issue":"4","key":"9855_CR76","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1200\/JCO.2009.22.9088","volume":"28","author":"AK Burnett","year":"2010","unstructured":"Burnett AK, et al. Attempts to optimize induction and consolidation treatment in acute myeloid leukemia: results of the MRC AML12 trial. J Clin Oncol. 2010;28(4):586\u201395.","journal-title":"J Clin Oncol"},{"issue":"3","key":"9855_CR77","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1111\/j.1365-2141.2011.08851.x","volume":"155","author":"BE Gibson","year":"2011","unstructured":"Gibson BE, et al. Results of a randomized trial in children with acute myeloid leukaemia: medical research council AML12 trial. Br J Haematol. 2011;155(3):366\u201376.","journal-title":"Br J Haematol"},{"issue":"27","key":"9855_CR78","doi-asserted-by":"publisher","first-page":"3360","DOI":"10.1200\/JCO.2012.47.4874","volume":"31","author":"AK Burnett","year":"2013","unstructured":"Burnett AK, et al. Optimization of chemotherapy for younger patients with acute myeloid leukemia: results of the medical research council AML15 trial. J Clin Oncol. 2013;31(27):3360\u20138.","journal-title":"J Clin Oncol"},{"issue":"1","key":"9855_CR79","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.29313","volume":"69","author":"KD Getz","year":"2022","unstructured":"Getz KD, et al. Cytarabine dose reduction in patients with low-risk acute myeloid leukemia: a report from the Children\u2019s Oncology Group. Pediatr Blood Cancer. 2022;69(1):e29313.","journal-title":"Pediatr Blood Cancer"},{"key":"9855_CR80","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.b4606","volume":"339","author":"DA Mulrooney","year":"2009","unstructured":"Mulrooney DA, et al. Cardiac outcomes in a cohort of adult survivors of childhood and adolescent cancer: retrospective analysis of the Childhood Cancer Survivor Study cohort. BMJ. 2009;339:b4606.","journal-title":"BMJ"},{"issue":"4","key":"9855_CR81","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1111\/bjh.14374","volume":"175","author":"M Jarfelt","year":"2016","unstructured":"Jarfelt M, Andersen NH, Hasle H. Is it possible to cure childhood acute myeloid leukaemia without significant cardiotoxicity? Br J Haematol. 2016;175(4):577\u201387.","journal-title":"Br J Haematol"},{"issue":"2","key":"9855_CR82","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1124\/pr.56.2.6","volume":"56","author":"G Minotti","year":"2004","unstructured":"Minotti G, et al. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev. 2004;56(2):185\u2013229.","journal-title":"Pharmacol Rev"},{"key":"9855_CR83","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/230182","volume":"2015","author":"E Gammella","year":"2015","unstructured":"Gammella E, et al. Iron-induced damage in cardiomyopathy: oxidative-dependent and independent mechanisms. Oxid Med Cell Longev. 2015;2015:230182.","journal-title":"Oxid Med Cell Longev"},{"key":"9855_CR84","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2022.113903","volume":"156","author":"Y Chen","year":"2022","unstructured":"Chen Y, Shi S, Dai Y. Research progress of therapeutic drugs for doxorubicin-induced cardiomyopathy. Biomed Pharmacother. 2022;156:113903.","journal-title":"Biomed Pharmacother"},{"key":"9855_CR85","doi-asserted-by":"crossref","unstructured":"van Dalen, E.C., et al., Cardioprotective interventions for cancer patients receiving anthracyclines. Cochrane Database Syst Rev. 2011;2011(6): Cd003917.","DOI":"10.1002\/14651858.CD003917.pub4"},{"issue":"2","key":"9855_CR86","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1001\/jama.2010.923","volume":"304","author":"RC Reulen","year":"2010","unstructured":"Reulen RC, et al. Long-term cause-specific mortality among survivors of childhood cancer. JAMA. 2010;304(2):172\u20139.","journal-title":"JAMA"},{"issue":"19","key":"9855_CR87","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1093\/jnci\/djn310","volume":"100","author":"AC Mertens","year":"2008","unstructured":"Mertens AC, et al. Cause-specific late mortality among 5-year survivors of childhood cancer: the Childhood Cancer Survivor Study. J Natl Cancer Inst. 2008;100(19):1368\u201379.","journal-title":"J Natl Cancer Inst"},{"issue":"12","key":"9855_CR88","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1016\/S2352-4642(22)00239-5","volume":"6","author":"EC de Baat","year":"2022","unstructured":"de Baat EC, et al. Primary cardioprotection with dexrazoxane in patients with childhood cancer who are expected to receive anthracyclines: recommendations from the International Late Effects of Childhood Cancer Guideline Harmonization Group. Lancet Child Adolesc Health. 2022;6(12):885\u201394.","journal-title":"Lancet Child Adolesc Health"},{"issue":"3","key":"9855_CR89","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1007\/s12012-019-09554-5","volume":"20","author":"BB Hasinoff","year":"2020","unstructured":"Hasinoff BB, Patel D, Wu X. The role of topoisomerase II\u03b2 in the mechanisms of action of the doxorubicin cardioprotective agent dexrazoxane. Cardiovasc Toxicol. 2020;20(3):312\u201320.","journal-title":"Cardiovasc Toxicol"},{"issue":"12","key":"9855_CR90","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1136\/heartjnl-2017-312103","volume":"104","author":"PA Henriksen","year":"2018","unstructured":"Henriksen PA. Anthracycline cardiotoxicity: an update on mechanisms, monitoring and prevention. Heart. 2018;104(12):971\u20137.","journal-title":"Heart"},{"issue":"8","key":"9855_CR91","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1200\/JCO.2015.60.8851","volume":"34","author":"BL Asselin","year":"2016","unstructured":"Asselin BL, et al. Cardioprotection and safety of dexrazoxane in patients treated for newly diagnosed T-cell acute lymphoblastic leukemia or advanced-stage lymphoblastic non-Hodgkin lymphoma: a report of the Children\u2019s Oncology Group Randomized Trial Pediatric Oncology Group 9404. J Clin Oncol. 2016;34(8):854\u201362.","journal-title":"J Clin Oncol"},{"issue":"21","key":"9855_CR92","doi-asserted-by":"publisher","first-page":"2398","DOI":"10.1200\/JCO.19.02856","volume":"38","author":"KD Getz","year":"2020","unstructured":"Getz KD, et al. Effect of dexrazoxane on left ventricular systolic function and treatment outcomes in patients with acute myeloid leukemia: a report from the Children\u2019s Oncology Group. J Clin Oncol. 2020;38(21):2398\u2013406.","journal-title":"J Clin Oncol"},{"issue":"10","key":"9855_CR93","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1016\/S1470-2045(10)70204-7","volume":"11","author":"SE Lipshultz","year":"2010","unstructured":"Lipshultz SE, et al. Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trial. Lancet Oncol. 2010;11(10):950\u201361.","journal-title":"Lancet Oncol"},{"issue":"5","key":"9855_CR94","doi-asserted-by":"publisher","first-page":"e254","DOI":"10.1097\/MPH.0000000000000838","volume":"39","author":"NJ Schloemer","year":"2017","unstructured":"Schloemer NJ, et al. Administration of dexrazoxane improves cardiac indices in children and young adults with acute myeloid leukemia (AML) while maintaining survival outcomes. J Pediatr Hematol Oncol. 2017;39(5):e254\u20138.","journal-title":"J Pediatr Hematol Oncol"},{"issue":"12","key":"9855_CR95","doi-asserted-by":"publisher","first-page":"2248","DOI":"10.1200\/JCO.22.02423","volume":"41","author":"EJ Chow","year":"2023","unstructured":"Chow EJ, et al. Dexrazoxane and long-term heart function in survivors of childhood cancer. J Clin Oncol. 2023;41(12):2248\u201357.","journal-title":"J Clin Oncol"},{"issue":"1","key":"9855_CR96","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.118.009122","volume":"8","author":"E Feijen","year":"2019","unstructured":"Feijen E, et al. Risk and temporal changes of heart failure among 5-year childhood cancer survivors: a DCOG-LATER Study. J Am Heart Assoc. 2019;8(1):e009122.","journal-title":"J Am Heart Assoc"},{"key":"9855_CR97","doi-asserted-by":"publisher","unstructured":"Horan MR, Sim JA, Krull KR, Baker JN, Huang IC. A Review of Patient-Reported Outcome Measures in Childhood Cancer. Children (Basel). 2022;9(10):1497. https:\/\/doi.org\/10.3390\/children9101497. PMID: 36291433; PMCID: PMC9601091.","DOI":"10.3390\/children9101497"},{"key":"9855_CR98","unstructured":"(CTFG), C.T.F.a.C.G. Recommendation Paper on the Initiation and Conduct of Complex Clinical Trials 2019. Accessed: 08\u201310\u20132024]; Available from: https:\/\/www.hma.eu\/fileadmin\/dateien\/Human_Medicines\/01-About_HMA\/Working_Groups\/CTFG\/2019_02_CTFG_Recommendation_paper_on_Complex_Clinical_Trials.pdf."},{"key":"9855_CR99","doi-asserted-by":"crossref","unstructured":"A-W, C., et al., SPIRIT 2013 Explanation and Elaboration: guidance for protocols of clinical trials. BMJ. ( 2013;346:e7586).","DOI":"10.1136\/bmj.e7586"},{"issue":"3","key":"9855_CR100","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1681\/ASN.2008030287","volume":"20","author":"GJ Schwartz","year":"2009","unstructured":"Schwartz GJ, et al. New equations to estimate GFR in children with CKD. J Am Soc Nephrol. 2009;20(3):629\u201337.","journal-title":"J Am Soc Nephrol"},{"key":"9855_CR101","doi-asserted-by":"crossref","unstructured":"Khoury, J.D., et al., The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms. Leukemia. 2022;36(7): 1703\u20131719.","DOI":"10.1038\/s41375-022-01613-1"},{"key":"9855_CR102","unstructured":"WHO Classification of Tumours Editorial Board. WHO Classification of Tumours: Paediatric Tumours. 5th ed. Vol. 7. Lyon (France): International Agency for Research on Cancer; 2022. ISBN: 978-92-832-4502-5."},{"key":"9855_CR103","doi-asserted-by":"crossref","unstructured":"Gruber TA, Zwaan CM. Central nervous system disease in pediatric acute myeloid leukemia.\u00a0Pediatr Blood Cancer. 2017;64(12):e26613.","DOI":"10.1002\/pbc.26782"},{"issue":"17","key":"9855_CR104","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1056\/NEJM198710223171717","volume":"317","author":"RD Mosteller","year":"1987","unstructured":"Mosteller RD. Simplified calculation of body-surface area. N Engl J Med. 1987;317(17):1098.","journal-title":"N Engl J Med"},{"issue":"12","key":"9855_CR105","first-page":"1275","volume":"131","author":"GJ Schuurhuis","year":"2018","unstructured":"Schuurhuis GJ, et al. Minimal\/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party. Blood, The Journal of the American Society of Hematology. 2018;131(12):1275\u201391.","journal-title":"Blood, The Journal of the American Society of Hematology"},{"key":"9855_CR106","unstructured":"EMA. Glossary - Regulatory terms. Accessed: 05\u201312\u20132024]; Available from: https:\/\/www.ema.europa.eu\/en\/about-us\/glossaries\/glossary-regulatory-terms."},{"issue":"2","key":"9855_CR107","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1200\/JCO.2007.12.7712","volume":"26","author":"JM Skolnik","year":"2008","unstructured":"Skolnik JM, et al. Shortening the timeline of pediatric phase I trials: the rolling six design. J Clin Oncol. 2008;26(2):190\u20135.","journal-title":"J Clin Oncol"},{"issue":"16","key":"9855_CR108","first-page":"3187","volume":"120","author":"U Creutzig","year":"2012","unstructured":"Creutzig U, et al. Diagnosis and management of acute myeloid leukemia in children and adolescents: recommendations from an international expert panel. Blood, The Journal of the American Society of Hematology. 2012;120(16):3187\u2013205.","journal-title":"Blood, The Journal of the American Society of Hematology"},{"issue":"12","key":"9855_CR109","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1182\/blood.2021011694","volume":"138","author":"JE Rubnitz","year":"2021","unstructured":"Rubnitz JE, Kaspers GJL. How I treat pediatric acute myeloid leukemia. Blood. 2021;138(12):1009\u201318.","journal-title":"Blood"},{"issue":"18","key":"9855_CR110","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1200\/JCO.21.01612","volume":"40","author":"JA Pollard","year":"2022","unstructured":"Pollard JA, et al. Sorafenib in combination with standard chemotherapy for children with high allelic ratio FLT3\/ITD+ acute myeloid leukemia: a report from the Children\u2019s Oncology Group Protocol AAML1031. J Clin Oncol. 2022;40(18):2023\u201335.","journal-title":"J Clin Oncol"},{"key":"9855_CR111","doi-asserted-by":"publisher","unstructured":"Umeda M, Liu YC, Karol SE, Klco JM. Novel classification system and high-risk categories of pediatric acute myeloid leukemia. Haematologica. 2025;110(9):1962\u201373. https:\/\/doi.org\/10.3324\/haematol.2024.285644. Epub 2025 Jan 9. PMID: 39781610; PMCID: PMC12399961.","DOI":"10.3324\/haematol.2024.285644"},{"issue":"22","key":"9855_CR112","doi-asserted-by":"publisher","first-page":"2574","DOI":"10.1182\/blood.2024026598","volume":"145","author":"G Egan","year":"2025","unstructured":"Egan G, Tasian SK. Precision medicine for high-risk gene fusions in pediatric AML: a focus on KMT2A, NUP98, and GLIS2 rearrangements. Blood. 2025;145(22):2574\u201386.","journal-title":"Blood"},{"key":"9855_CR113","doi-asserted-by":"crossref","unstructured":"Candoni, A. and G. Coppola, A 2024 Update on menin inhibitors. A new class of target agents against KMT2A-rearranged and NPM1-mutated acute myeloid leukemia. Hematol Rep, 2024;16(2): 244\u2013254.","DOI":"10.3390\/hematolrep16020024"}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13063-026-09855-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-026-09855-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-026-09855-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T04:23:46Z","timestamp":1788150226000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13063-026-09855-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,20]]},"references-count":113,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["9855"],"URL":"https:\/\/doi.org\/10.1186\/s13063-026-09855-5","relation":{},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,20]]},"assertion":[{"value":"13 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The CHIP-AML22 Master protocol and Quizartinib protocol have independently been assessed and approved in CTIS (EU CT 2023-504999-25-00 and EU CT 2023-505000-27-01). The assessment process for Part I was led by the Reporting Member State, The Netherlands. Part II documents were assessed separately by all other Member States Concerned, on which further details can be found in the EU Clinical Trial Register.Patients will only participate when oral and written consent have been provided by the patient, or their legal guardians by proxy where appropriate.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"YD is employed by Daiichi Sankyo Inc. She acts in adherence to the Good Publication Practice guidelines for pharmaceutical companies (GPP2022). GJK, MVH, RB, BFG, SI, JK, HVT, DGV, NW and MZ are employed by the Princess M\u00e1xima Center, which center receives institutional funding from the Sponsor of the linked Quizartinib trial. All other authors declare no conflict of interest.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"555"}}